Program
HDM1002
A development code. Also written as “HDM1002 200 mg”, “HDM1002 400 mg” and “HDM1002 100 mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Overweight · Obesity, led by Huadong Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huadong Medicine | 1311 open or running | phase 3since Mar 13, 2025 | Jun 13, 2024 | Feb 16, 2027phase 3 · NCT07082114 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 13, 2024First studies: 2 phase 2 studiesFirst studyNCT06500299, NCT06481085
- Jul 9, 2024Phase 1 study in Glucagon-Like Peptide-1 Receptor AgonistsNCT06520540 · 72 planned · China
- Aug 13, 20242 phase 1 studies in Healthy Adult SubjectNCT06562088, NCT06576401
- Sep 3, 20242 phase 1 studies in Healthy Adult SubjectNCT06601517, NCT06608329
- Mar 13, 2025Phase 3 study in OverweightNCT06885021 · 780 planned
- May 15, 2025Phase 1 study in Hepatic ImpairmentNCT06985615 · 40 planned · China
- Jul 10, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07082114 · 800 planned · China
- Sep 1, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07193459 · 360 planned · China
- Nov 18, 2025Phase 1 study in Overweight SubjectNCT07331389 · 111 planned · China
- May 6, 2026Phase 1 study in Healthy Adult SubjectNCT07594847 · 72 planned · China
Ahead
- Feb 16, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07082114
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07594847Healthy Adult Subject · China | 1 | Recruiting | Sep 25, 2026 | 72 |
| NCT07331389Overweight Subject · China | 1 | Recruiting | Jan 12, 2026 | 111 |
| NCT07193459Diabetes Mellitus, Type 2 · China | 3 | Recruiting | Oct 10, 2026 | 360 |
| NCT07082114Diabetes Mellitus, Type 2 · China | 3 | Recruiting | Feb 16, 2027 | 800 |
| NCT06985615Hepatic Impairment · China | 1 | Recruiting | Jan 14, 2026 | 40 |
| NCT06885021Overweight | 3 | Not yet recruiting | May 30, 2026 | 780 |
| NCT06608329Healthy Adult Subject · China | 1 | Not yet recruiting | Nov 2024 | 33 |
| NCT06601517Healthy Adult Subject · China | 1 | Not yet recruiting | Feb 2025 | 30 |
| NCT06576401Healthy Adult Subject · China | 1 | Recruiting | Oct 2024 | 10 |
| NCT06562088Healthy Adult Subject · China | 1 | UNKNOWN | Nov 19, 2024 | 40 |
| NCT06520540Glucagon-Like Peptide-1 Receptor Agonists · China | 1 | Not yet recruiting | Nov 30, 2024 | 72 |
| NCT06500299Overweight | 2 | Not yet recruiting | Oct 30, 2024 | 180 |
| NCT06481085Diabetes Mellitus, Type 2 · China | 2 | Completed | May 30, 2025 | 324 |
How it is read
Names in the registry
- “HDM1002 200 mg”, 4 entries
- “HDM1002 400 mg”, 4 entries
- “HDM1002”, 3 entries
- “HDM1002 100 mg”, 2 entries
- “HDM1002 200 mg QD 12weeks”, 2 entries
Codes read as this program: HDM1002.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 3 studies
- Overweight, 2 studies
- Obesity, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.